Acumen reports FY2025 net loss $121.3M; cash $116.9M; ALTITUDE-AD topline due late 2026

Acumen Pharmaceuticals, Inc.

Net loss $121.3M for FY2025 ($102.3M in FY2024); R&D expenses rose to $104.9M.
Cash, equivalents and marketable securities $116.9M as of Dec 31, 2025; expected to fund operations into early 2027.
Phase 2 ALTITUDE-AD (sabirnetug) topline results expected late 2026; OLE dosing commenced Nov 2025.
$35.75M private placement closed March 2026 to advance Enhanced Brain Delivery (EBD) program; IND filing targeted mid-2027.
EBD program candidates showed up to 40-fold brain exposure in NHPs; low anemia risk; subcutaneous potential.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Acumen Pharmaceuticals, Inc. reported the year ended December 31, 2025 results: net income Net loss was $121.3 million.

Period: the year ended December 31, 2025
Net income: Net loss was $121.3 million
Result: reported results

Exact text from the filing

Net loss was $121.3 million for the year ended Dec. 31, 2025, compared to $102.3 million for the year ended Dec. 31, 2024.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-021189

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.